FDA
-
-
-
-
-
-
-
Harbour BioMed Announces 2023 Interim Results
-
-
-
-
-
-
-
Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003
-
326,640 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

